ZURICH |
Mon Dec 10, 2012 6:17pm EST
ZURICH (Reuters) – Novartis AG’s blood cancer drug Tasigna is improved during treating a form of ongoing myeloid leukemia than a comparison drug Glivec, according to information from dual late-stage trials, boosting prospects for a oncology franchise.
Novartis is anticipating to remonstrate doctors to switch patients to Tasigna to defense a sales once Glivec, one of a best-selling medicines, loses obvious exclusivity in 2015.
The latest data, that are being presented during a American Society of Hematology’s (ASH) annual meeting, examined a advantages of Tasigna in patients with Philadelphia chromosome-positive ongoing myeloid leukemia.
Two-year information from a ENESTcmr hearing showed patients who still had justification of residual illness after long-term diagnosis with Glivec achieved undetectable levels of a illness after switching to Tasigna.
More than twice as many patients treated with Tasigna continued to uncover undetectable levels of a illness compared with Glivec, according to a data. Novartis pronounced a formula were statistically significant.
Meanwhile, four-year information from a ENESTnd hearing showed some-more than 3 times as many patients being treated with Tasigna as a frontline therapy gifted a rebate in a turn of illness contra Glivec, marketed as Gleevec in a United States.
Novartis skeleton to start a clinical hearing in early 2013 to exam either some patients might be means to stop diagnosis after achieving a postulated response to therapy.
Other information also presented during ASH showed that Novartis’ drug Jakavi – that gained EU capitulation in Aug – significantly reduced a illness weight in patients with myelofibrosis, a singular blood cancer with singular diagnosis options.
Follow adult information from a late-stage investigate showed that scarcely half of patients treated with Jakavi achieved a rebate of during slightest 35 percent in spleen volume, Novartis said.
(Reporting by Caroline Copley; Editing by David Holmes and Tim Dobbyn)
Source: Health Medicine Network